title: High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07.
abstract: OBJECTIVE
  The effectiveness of synchronous carboplatin, etoposide, and radiation therapy was prospectively assessed in a group of patients with high-risk Merkel cell carcinoma (MCC) of the skin.
  
  
  METHODS
  Patients were eligible if they had disease localized to the primary site and nodes, and were required to have at least one of the following high risk features: recurrence after initial therapy, involved nodes, primary tumor size greater than 1 cm, gross residual disease after surgery, or occult primary with nodes. Radiation was delivered to the primary site and nodes to a dose of 50 Gy in 25 fractions over 5 weeks and synchronous carboplatin (area under the curve, 4.5) and intravenous etoposide 80 mg/m2 days 1 to 3 was given in weeks 1, 4, 7, and 10. The median age of the group was 67 (range, 43-86) years, and there were 39 males and 14 females. Involved nodes (stage II) were present in 33 cases (62%). The sites involved were head and neck (22 patients), occult primary (13 patients), upper limb (eight patients), lower limb (eight patients), and trunk (two patients).
  
  
  RESULTS
  Fifty-three patients were entered between 1996 and 2001. The median potential follow-up was 48 months. There were no treatment related deaths. The 3-year overall survival, locoregional control, and distant control were 76%, 75%, and 76%, respectively. Tumor site and the presence of nodes were factors that were predictive for local control and survival. Multivariate analysis indicated that the major factor influencing survival was the presence of nodes; however, this was not a significant factor in locoregional control.
  
  
  CONCLUSIONS
  High levels of locoregional control and survival have been achieved with the addition of chemotherapy to radiation treatment for high-risk MCC of the skin. The role of chemoradiotherapy for high-risk MCC warrants further investigation.
authors.affiliation: Mater Queensland Radium Institute, Raymond Tee, South Brisbane, QLD 4101 Australia. michael_poulsen@health.qld.gov.au
authors.forename: Michael
authors.initials: M
authors.lastname: Poulsen
authors.forename: Danny
authors.initials: D
authors.lastname: Rischin
authors.forename: Euan
authors.initials: E
authors.lastname: Walpole
authors.forename: Jennifer
authors.initials: J
authors.lastname: Harvey
authors.forename: John
authors.initials: J
authors.lastname: Mackintosh
authors.forename: Jill
authors.initials: J
authors.lastname: Ainslie
authors.forename: Chris
authors.initials: C
authors.lastname: Hamilton
authors.forename: Jacqui
authors.initials: J
authors.lastname: Keller
authors.forename: Lee
authors.initials: L
authors.lastname: Tripcony
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D015266:Carcinoma, Merkel Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy; D011446:Prospective Studies; D018787:Radiation Oncology; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D012955:Societies, Medical; D015996:Survival Rate
chemical_list: D005047:Etoposide; D016190:Carboplatin